Non-alcoholic Steatohepatitis Treatment Market

The Non-alcoholic Steatohepatitis (NASH) treatment market encompasses pharmaceutical therapies designed to address liver inflammation, fibrosis, and insulin resistance associated with the disease. The primary customers are patients with NASH, accessed through healthcare systems, with pharmaceutical companies developing the treatments. Key growth drivers include the rising global prevalence of risk factors like obesity and type 2 diabetes, an aging population, and an increasing pipeline of innovative drugs advancing through clinical trials.